Unbound MEDLINE

A biodegradable filament for controlled drug delivery. Journal of controlled release : official journal of the Controlled Release Society [J Control Release] Journal article

 
TitleA biodegradable filament for controlled drug delivery.
Author(s)Mack BC, Wright KW, Davis ME 
InstitutionChemical Engineering, California Institute of Technology, Pasadena, CA 91125.
SourceJ Control Release 2009 Jun 27.
AbstractBiodegradable filaments (diameters of 250-300 mum) for the controlled delivery of dexamethasone or levofloxacin are described. Filaments are prepared by wet-spinning solutions of poly(lactide-co-glycolide) (PLGA) and drug dissolved in dimethyl sulfoxide (DMSO) into a coagulation bath of water. Compositional analyses of the filaments by independent measurements of drug, DMSO, water, and polymer give drug loadings up to 40% of filament mass and drug retention (drug in filament per drug in solution) greater than 40%. Drug release kinetics, and thermal and mechanical properties, of the filaments are reported. Three filaments with levofloxacin contents of 46+/-2, 85+/-4, and 36+/-2 mug/cm (denoted 506-L1, 506-L2, and 506-L3, respectively) are implanted in the conjunctiva of New Zealand white rabbits. The time dependent, in-vivo tear concentrations of levofloxacin from filament implants in New Zealand white rabbit eyes are in general agreement with the results from the in-vitro release profiles, with one of the filaments (506-L1) showing effective levels of levofloxacin in the tears for 6 days. The filaments are generally well tolerated by the rabbits. Filament failure occurs at 6-8 days within the rabbit eyes, essentially the same time to failure observed from in-vitro mechanical properties testing results.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19567255
  
Advertise on this site.